CT 200

Drug Profile

CT 200

Alternative Names: CT200

Latest Information Update: 21 Jan 2011

Price : $50

At a glance

  • Originator Celleron Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Cell cycle protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 21 Jan 2011 This programme is in active development
  • 14 Nov 2007 Phase-I clinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top